A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder
The primary endpoint of the randomised study was not met. Further research on brexpiprazole in BPD is warranted based on possible efficacy signals at other time points and its safety profile.ClinicalTrials.gov identifiers: NCT04100096, NCT04186403. Funding: Otsuka, Lundbeck.
Authors
- Jon E. Grant (ORCID: https://orcid.org/0000-0001-7784-7021)
- Denise Chang
- Nanco Hefting
- Claudette Brewer
- Brian Rothman (ORCID: https://orcid.org/0009-0006-5780-2559)
- Robert D. McQuade
- Mary Hobart
Institutions
- Lundbeck (Denmark) (DK)
- University of Chicago (US)
- Otsuka (United States) (US)
Publication Details
- Journal
- Acta Neuropsychiatrica
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1017/neu.2024.31
- Citations
- 2
- Primary Topic
- Personality Disorders and Psychopathology
- Type
- article
- Field-Weighted Citation Impact
- 1.28